Program
SIM0518
A development code. Also written as “SIM0518+Bupropion”, “SIM0518+Midazolam” and “SIM0518+Repaglinide”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Simcere Pharmaceutical Group.
Furthest: phase 1, since Oct 22, 20261 company-led study, 1 open or runningNext primary completion: Dec 1, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 11 open or running | phase 1since Oct 22, 2026 | Oct 22, 2026 | Dec 1, 2028phase 1 · NCT07912268 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2026First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07912268 · 270 planned · China
Ahead
- Dec 1, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07912268
TargetBeta
“SIM0518 is an oral, next-generation, highly selective ALK/ROS1 dual inhibitor.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07912268Carcinoma, Non-Small-Cell Lung · China | 1 | Not yet recruiting | Dec 1, 2028 | 270 |
How it is read
Names in the registry
- “SIM0518”, 1 entry
- “SIM0518+Bupropion”, 1 entry
- “SIM0518+Midazolam”, 1 entry
- “SIM0518+Repaglinide”, 1 entry
- “SIM0518+Tolbutamide”, 1 entry
Codes read as this program: SIM0518.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.